Anna F. Farago, MD, PhD
Advertisement
Articles by Anna F. Farago, MD, PhD
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Advertisement
Latest Updated Articles
Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLCPublished: June 11th 2019 | Updated:
Dr. Anna F. Farago New Cytotoxic Strategies for Relapsed Small-Cell Lung CancerPublished: June 12th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Dose Escalation Did Not Improve Efficacy/QOL in Anal Cancer
2
FDA Receives BLA for Ivonescimab Combo in Advanced/Metastatic EGFR+ NSCLC
3
FDA Issues New CRL for Tabelecleucel in Epstein Barr Virus–Positive PTLD
4
Atezolizumab Combo Does Not Significantly Boost Survival in Ovarian Cancer
5